Your browser doesn't support javascript.
loading
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Zhao, Ning; Wu, Zhuo-Peng; Yang, Jie; Feng, Wei-Neng; Yang, Sheng-Li; Luo, Ying; Ye, Jun; Wang, Fei; Zhang, Xiao-Wen; Xiao, Ye; Wu, Ling-Ling; Gu, Wei-Quan.
Afiliación
  • Zhao N; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Wu ZP; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Yang J; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Feng WN; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
  • Yang SL; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Luo Y; Department of Traditional Chinese Medicine, The First People's Hospital of Foshan, Foshan, China.
  • Ye J; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Wang F; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Zhang XW; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Xiao Y; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Wu LL; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
  • Gu WQ; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China. fsgwquan@21cn.com.
World J Surg Oncol ; 21(1): 45, 2023 Feb 13.
Article en En | MEDLINE | ID: mdl-36782320
ABSTRACT

BACKGROUND:

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is still under investigation as adjuvant treatment for early-stage disease. Here, we performed a meta-analysis to evaluate the efficacy of adjuvant EGFR-TKI versus non-EGFR-TKI treatment in patients with completely resected non-small cell lung cancer (NSCLC) harboring EGFR mutation.

METHODS:

Two investigators independently extracted data from databases. A meta-analysis was performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The protocol was registered in PROSPERO (ID CRD42022316481). The primary outcome was disease-free survival (DFS) in patients with EGFR mutation, measured as the hazard ratio (HR). Other outcomes (of subgroup analyses) included overall survival (OS) and DFS.

RESULTS:

After the systematic screening, eight studies with a total of 3098 patients with stage IB-IIIA NSCLC were included. The results show that in patients with EGFR mutation, the DFS in the adjuvant EGFR-TKI group was significantly superior to that in the control group, with a HR of 0.47 (95% confidence interval [CI] 0.30-0.74; P = 0.001). In subgroup analyses of DFS, the benefit was observed in the EGFR-TKI group versus the chemotherapy group (HR 0.50, 95% CI 0.30-0.84; P = 0.009), the EGFR-TKI combined with chemotherapy group versus the chemotherapy group (HR 0.37, 95% CI 0.16-0.85; P = 0.02), and in stage IIA-IIIA NSCLC (HR 0.45, 95% CI 0.27-0.74; P = 0.002). However, the benefit of DFS did not translate into improved OS in the whole population (HR 0.79, 95% CI 0.54-1.14; P = 0.20).

CONCLUSION:

EGFR-TKIs prolonged DFS but not OS in patients with completely resected stage II-IIIA NSCLC harboring EGFR mutation. Longer follow-ups and new clinical trials that can result in changes in clinical practice are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: China